Volume 152, Issue 6, Pages (December 2017)

Slides:



Advertisements
Similar presentations
Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,
Advertisements

내과 R2 이지훈 N Engl J Med Sep 8.
Volume 129, Issue 3, Pages (March 2006)
Volume 104, Issue 6, Pages (December 1993)
Bronchial Hyperresponsiveness in the Assessment of Asthma Control
Bronchial Hyperresponsiveness in the Assessment of Asthma Control
How Well Does CAPTURE Translate?
Volume 115, Issue 2, Pages (February 1999)
Volume 119, Issue 4, Pages (April 2001)
Volume 138, Issue 3, Pages (September 2010)
Volume 137, Issue 6, Pages (June 2010)
Volume 120, Issue 6, Pages (December 2001)
Volume 148, Issue 1, Pages (July 2015)
Single-Breath Washout Tests to Assess Small Airway Disease in COPD
Clinical and Personality Profiles and Survival in Patients With COPD
Volume 148, Issue 1, Pages (July 2015)
Volume 112, Issue 2, Pages (August 1997)
Volume 132, Issue 5, Pages (November 2007)
Improving the Management of COPD in Women
Volume 149, Issue 5, Pages (May 2016)
Volume 143, Issue 1, Pages (January 2013)
Volume 151, Issue 3, Pages (March 2017)
Practical Recommendations for COPD:
Volume 140, Issue 2, Pages (August 2011)
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Volume 143, Issue 6, Pages (June 2013)
Volume 153, Issue 1, Pages (January 2018)
Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double- Blind Study in Men With Diabetes Mellitus  Irwin Goldstein, MD,
What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?
Volume 10, Issue 7, Pages (July 2018)
Volume 153, Issue 4, Pages (April 2018)
Decreased Serum Sirtuin-1 in COPD
Volume 153, Issue 5, Pages (May 2018)
Precision Medicine Urgency
Volume 146, Issue 6, Pages (December 2014)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
Volume 154, Issue 6, Pages (December 2018)
Volume 151, Issue 1, Pages (January 2017)
Volume 151, Issue 2, Pages (February 2017)
Improving the Management of COPD in Women
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance 
A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies  Linda.
Volume 153, Issue 6, Pages (June 2018)
Volume 151, Issue 3, Pages (March 2017)
Volume 154, Issue 4, Pages (October 2018)
Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E
Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to exacerbation history (intent-to-treat.
Cough in Patients With Lung Cancer
Minimum clinically important difference for the COPD Assessment Test: a prospective analysis  Dr Samantha S C Kon, MBBS, Jane L Canavan, PhD, Sarah E.
Volume 143, Issue 1, Pages (January 2013)
Imaging for the Management of Community-Acquired Pneumonia
Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients.
Volume 154, Issue 5, Pages (November 2018)
Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis  Gary R. Lichtenstein,
POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis 
Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to chronic obstructive pulmonary.
Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb 
High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects  William Busse, MD, Sheldon Spector, MD, Karin Rosén,
HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.
A Scoring Application for the St. George’s Respiratory Questionnaire
Volume 146, Issue 6, Pages (December 2014)
Volume 150, Issue 4, Pages (October 2016)
Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J
POINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? Yes 
Larry C. Borish, MDa, Harold S
Practical Recommendations for COPD:
Volume 82, Issue 11, Pages (December 2012)
Mean (95% CI) change in Clinical COPD Questionnaire (CCQ) with pulmonary rehabilitation, according to achievement (+) or non-achievement (−) of the established.
Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting 
Presentation transcript:

Volume 152, Issue 6, Pages 1169-1178 (December 2017) Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD  Fernando J. Martinez, MD, FCCP, Leonardo M. Fabbri, MD, FCCP, Gary T. Ferguson, MD, FCCP, Chad Orevillo, MPH, Patrick Darken, PhD, Ubaldo J. Martin, MD, Colin Reisner, MD, FCCP  CHEST  Volume 152, Issue 6, Pages 1169-1178 (December 2017) DOI: 10.1016/j.chest.2017.07.007 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Relationship between CAT and mMRC dyspnea grade (pooled ITT population). CAT = COPD Assessment Test; mMRC = modified Medical Research Council. CHEST 2017 152, 1169-1178DOI: (10.1016/j.chest.2017.07.007) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Relationship between baseline CAT score and the magnitude of improvement in (A) morning predose trough FEV1 or (B) peak FEV1 at week 24 observed in the GFF MDI group compared with monocomponent MDIs or placebo MDI. All treatment differences for the GFF MDI vs individual monocomponent MDIs and the placebo MDI were associated with P < .05. FF = formoterol fumarate; GFF = glycopyrrolate/formoterol fumarate; GP = glycopyrrolate; ITT = intent to treat; LSM = least squares mean; MDI = metered dose inhaler. See Figure 1 legend for expansion of other abbreviations. CHEST 2017 152, 1169-1178DOI: (10.1016/j.chest.2017.07.007) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Relationship between baseline CAT score and (A) the magnitude of improvement in change from baseline in the SGRQ total score at week 24 and (B) the proportion of patients achieving the MCID for SGRQ total score at week 24 for GFF MDI vs comparator (95% CI). MCID was defined as a four-unit improvement in SGRQ total score. *P < .05; †P < .01. MCID = minimum clinically important difference; SGRQ = St. George’s Respiratory Questionnaire. See Figure 1 and 2 legends for expansion of other abbreviations. CHEST 2017 152, 1169-1178DOI: (10.1016/j.chest.2017.07.007) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Time to first moderate or severe exacerbation, hazard ratio for GFF MDI vs comparator (95% CI) stratified by baseline CAT score. Data shown are for patients with evaluable data for each end point. *P < .05; †P < .01. HR = hazard ratio. See Figure 1 and 2 legends for expansion of other abbreviations. CHEST 2017 152, 1169-1178DOI: (10.1016/j.chest.2017.07.007) Copyright © 2017 The Authors Terms and Conditions